Welcome to our dedicated page for Absci SEC filings (Ticker: ABSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Absci’s dense biotech disclosures can feel like parsing a lab notebook written in code. R&D capitalization rules, milestone accounting, and rapidly evolving regulatory language turn every 10-K into a puzzle. That’s why our SEC filings hub tackles the complexity head-on, turning “Absci insider trading Form 4 transactions” and clinical-stage risk factors into clear, decision-ready insights.
Need the latest numbers? Each Absci quarterly earnings report 10-Q filing is indexed the moment it posts to EDGAR, with AI-powered summaries highlighting cash runway, collaboration revenue swings, and pipeline spend. Material news breaks fast too—our platform pushes alerts and plain-English takeaways for every Absci 8-K material events explained entry, so you know exactly what changed and why.
Curious whether executives are buying ahead of data readouts? Track Absci Form 4 insider transactions real-time and dive deeper with Absci executive stock transactions Form 4 tables already totaled for you. Preparing a valuation model? The Absci annual report 10-K simplified section distills 200-plus pages into key financials, IP assets, and regulatory risks. Governance analysts can compare board pay with the Absci proxy statement executive compensation snapshot, while newcomers benefit from understanding Absci SEC documents with AI through concise, jargon-free briefs.
- AI summaries translate complex biotech language into investor-ready points.
- Real-time feeds cover every form—from 10-K to 8-K—for complete Absci earnings report filing analysis.
- Searchable database links each disclosure to the questions professionals actually ask.
Spend less time decoding filings and more time acting on insights—our platform turns Absci’s regulatory maze into a straight path.
Absci Corporation reported third‑quarter 2025 results. Partner program revenue was $0.378 million, down from $1.701 million a year ago, reflecting milestone timing and program mix. The company posted a net loss of $28.7 million (basic and diluted loss per share $0.20) on total operating expenses of $30.5 million, including $19.2 million in R&D. For the first nine months, revenue was $2.15 million and net loss was $85.6 million.
Liquidity remained solid with $152.5 million in cash, cash equivalents and marketable securities as of September 30, 2025. The company strengthened its balance sheet in 2025 through a $20.0 million PIPE with AMD, a July offering yielding $46.7 million in net proceeds, and $35.7 million via a prior ATM program. Shares outstanding were 150,371,531 as of October 31, 2025.
Program updates: ABS‑101 Phase 1 in healthy volunteers showed extended half‑life versus first‑generation anti‑TL1A programs with a favorable safety profile; Absci plans to seek a partner after trial completion. ABS‑201 received HREC approval in Australia, with first dosing targeted for December 2025. A subsequent event settled Totient contingent consideration for approximately $7.6 million and released $8.7 million from escrow.
Absci Corporation announced its financial results for the third quarter ended September 30, 2025. The company furnished a press release as Exhibit 99.1 under Item 2.02, and noted that this information is being furnished and not deemed filed under the Exchange Act.
Absci also filed a Fall 2025 corporate presentation as Exhibit 99.2, which includes internal pipeline program updates and is available in the News & Events section of its website.
Absci Corporation entered into a Letter Agreement with SBGH, LLC that amends the 2021 Totient merger terms and sets a final distribution of milestone consideration. The agreement provides that certain former Totient stockholders will receive approximately $7.6 million, and Absci will receive approximately $8.7 million, in full satisfaction of all potential milestone payments under the merger agreement.
The Letter Agreement, dated October 31, 2025, is filed as an exhibit, with certain portions redacted as immaterial and confidential.
Absci (ABSI) CEO and Director reported a routine tax withholding on restricted stock unit vesting. On 10/14/2025, 23,293 shares of common stock were withheld at $3.68 per share under transaction code F, which reflects shares withheld to satisfy taxes and not an open-market trade.
Following this event, the reporting person beneficially owned 8,361,328 shares directly. An additional 2,269,987 shares are held by Brittany McClain and are subject to a voting agreement and proxy that entitles the reporting person to vote those shares.
Absci (ABSI) reported an insider transaction on Form 4. The company’s CFO/CBO recorded a Code F transaction on 10/14/2025, reflecting 387 shares of common stock withheld by the issuer at $3.68 to satisfy taxes upon RSU vesting. Following this withholding, the reporting person directly owns 409,354 shares. The filing notes this was for tax withholding and not a discretionary trade.
Absci (ABSI) reported an insider Form 4 for its Chief Innovation Officer detailing tax withholding related to RSU vesting. On 10/14/2025, 3,092 shares of common stock were withheld under transaction code F at $3.68 to satisfy taxes, which the footnote clarifies was not a discretionary trade. Following this administrative transaction, the officer directly beneficially owns 324,172 shares.
Absci (ABSI) disclosed a Form 4 for a company officer (SVP, CAO). On 10/14/2025, 21,950 shares of common stock were withheld under code “F” to cover tax obligations upon the vesting of restricted stock units. The withholding price was $3.68 per share. After this transaction, the officer directly holds 161,283 shares. The filing states the withholding was for taxes related to RSU vesting and was not a discretionary trade.
Menelas N. Pangalos, a director of Absci Corp (ABSI), reported an open-market purchase of 95,785 shares of Absci common stock on 09/22/2025 at a price of $2.66 per share. After the transaction, Mr. Pangalos beneficially owned 113,960 shares. The filing states the purchase was made in accordance with the issuer's trading policies. The Form 4 was executed by Shelby Walker as attorney-in-fact on 09/22/2025.
Insider purchase by Absci Corp officer: Todd Bedrick, listed as SVP and CAO, reported an open-market purchase of 10,000 shares of Absci Corp (ABSI) on 09/22/2025 at a reported price of $2.70 per share. Following the transaction he beneficially owned 180,428 shares, held in a direct capacity. The Form 4 was signed by an attorney-in-fact on his behalf and notes the purchase was made in accordance with the issuer's trading policies.
Absci Corporation insider report: This Form 4 shows that Zachariah Jonasson, an officer serving as CFO/CBO, had 8,319 shares of Absci common stock withheld on 08/31/2025 to satisfy tax withholding related to the vesting and settlement of restricted stock units. The shares were withheld at a reported price of $2.39 per share. After the withholding, Mr. Jonasson is reported to beneficially own 409,741 shares of Absci common stock as a direct holder. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/02/2025.
FAQ
What is the current stock price of Absci (ABSI)?
What is the market cap of Absci (ABSI)?
